David A. Siegel I Mab Call Options Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMAB
# of Institutions
40Shares Held
15.8MCall Options Held
10.2KPut Options Held
0-
Hhlr Advisors, Ltd. Grand Cayman, E95.98MShares$31.2 Million0.6% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$21.8 Million3.04% of portfolio
-
Ariose Capital Management LTD Central, Hong Kong, K31.7MShares$8.9 Million2.68% of portfolio
-
Candriam S.C.A.1.13MShares$5.91 Million0.02% of portfolio
-
Sg Americas Securities, LLC876KShares$4.57 Million0.01% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $434M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...